Binkui Li

Spezialisierung: Hepatobiliärer Chirurg/-in
Arbeitsplatz: China, Kanton, Sun Yat-sen University Cancer Center (SYSUCC)
Als Professor, Doktorvater und Direktor der Abteilung für Leberchirurgie am Sun Yat-sen University Cancer Center leitet Binkui Li eine multidisziplinäre Versorgung bei Leberkrebs, die Chirurgie mit vaskulärer Interventionstherapie, zielgerichteter Therapie und Immuntherapie verbindet. Sein klinischer Schwerpunkt liegt auf der Konversionstherapie bei fortgeschrittenem Leberkrebs – mit dem Ziel, chirurgische Möglichkeiten für ursprünglich inoperable Fälle zu schaffen – und er ist ein erfahrenes MDT-Mitglied für Darmkrebs, einschließlich der Chirurgie von Lebermetastasen bei Darmkrebs.
Binkui Li ist Spezialist am Sun Yat-sen University Cancer Center, wo er als Professor, Doktorvater und Direktor der Leberchirurgie tätig ist. Er behandelt Leberkrebs mit einem multidisziplinären Programm, das Chirurgie, vaskuläre Interventionstherapie, zielgerichtete Therapie und Immuntherapie kombiniert. Ein wesentliches Merkmal ist sein Ansatz der Konversionstherapie bei fortgeschrittenem Leberkrebs, um Operationen in Fällen zu ermöglichen, die ursprünglich als inoperabel galten.

Dienstleistungen des Arztes

Wie läuft es für Sie mit uns?

1 von 3

Die Informationen über diesen Arzt sind vollständig und klar

Stimme nicht zu

Stimme stark zu

Qualifikationen

With conversion therapy designed to turn initially unresectable advanced liver cancers into operable cases, Binkui Li focuses on the “multidisciplinary, individualized, systemic treatment” pathway for every patient at Sun Yat-sen University Cancer Center. As Professor, PhD supervisor, and Director of the Liver Surgery Department, he coordinates liver cancer treatment that can include surgery, vascular interventional therapy, targeted therapy, and immunotherapy. His work emphasizes improving curative outcomes and quality of life by tailoring treatment programs to disease stage and biology. Among his core clinical priorities is conversion therapy for advanced liver cancer, which is intended to create surgery opportunities for cases that cannot be resected at presentation. He also participates as an expert member of the Multi-Disciplinary Team (MDT) for colorectal cancer, where he is skilled in surgery of liver metastasis from colorectal cancer. In practice, this means patients are evaluated through a liver-focused surgical lens while systemic options are considered early as part of a single plan.

Education

Education details are not specified in the provided profile materials.

Work experience

Professor and Director of Liver Surgery Department, Sun Yat-sen University Cancer Center (current role).

Clinical focus and techniques

At Sun Yat-sen University Cancer Center, Binkui Li specializes in multidisciplinary management of liver cancers, integrating operative and non-operative oncologic strategies into one individualized plan.

Conversion therapy for advanced liver cancer to create surgery opportunities for initially unresectable cases.
Surgery of liver metastasis from colorectal cancer as part of colorectal cancer MDT decision-making.
Multidisciplinary treatment of liver cancers including surgery.
Vascular interventional therapy for liver cancer.
Targeted therapy and immunotherapy as components of systemic treatment programs.

Professional societies and certifications

Memberships and certifications are not specified in the provided profile materials.

Academic output

Academic output details are not specified in the provided profile materials.

Courses and advanced training

Courses and advanced training details are not specified in the provided profile materials.

Awards and recognition

Awards are not specified in the provided profile materials.

For international patients, the advantage of working with a specialist at Sun Yat-sen University Cancer Center is access to coordinated liver cancer decision-making across surgical and systemic options. The clinic’s liver surgery program is structured around multidisciplinary planning, which is especially relevant for advanced-stage disease where timing of conversion therapy and resection matters.